Global Transthyretin Amyloid Cardiomyopathy Market - 2022-2029

Global Transthyretin Amyloid Cardiomyopathy Market - 2022-2029

Market Overview

Transthyretin Amyloid Cardiomyopathy Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 31.1 % during the forecast period (2022-2029).

Transthyretin amyloid cardiomyopathy is an underdiagnosed and potentially fatal disease. It is characterized by deposits of amyloid protein fibrils in the left ventricle walls, the heart's main pumping chamber. In transthyretin amyloid cardiomyopathy, the amyloid protein is mad left ventricle wall syretin, a transport protein created in the liver to carry thyroxine (a thyroid hormone) retinol (vitamin A) to the necessarily required places in the body. The amyloid protein deposits cause the heart walls to become stiff, resulting in the inability of the left ventricle to relax and fill with blood properly and adequately squeeze to pump blood out of the heart. Due to genetic mutation or aging, the transthyretin does not normally assemble, clump together, and shape itself into amyloid fibrils. The fibrils travel through the bloodstream and deposit in many organs, including the heart. As fibrils accumulate in the tissue, they thicken and stiffen the myocardium or wall of the heart. It causes cardiomyopathy and, ultimately, heart failure. The transthyretin amyloid cardiomyopathy market growth is driven by several factors, such as increased geriatric population, rising public awareness, the launch of new drugs and favorable government initiatives.

Market Dynamics: Increase in geriatric population drives market growth.

The geriatric population is the most vulnerable population to transthyretin amyloid cardiomyopathy due to the abnormal assembly of transthyretin in aged people. It is an unrecognized cause of heart failure in older adults resulting from myocardial deposition of misfolded transthyretin or pre-albumin. According to a report published by the World Health Organization in 2021, By 2030, 1 in 6 people in the world will be aged 60 years or over. The share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion), according to the estimation. The number of persons aged 80 years or older is expected to triple between the years 2020 and 2050 to reach 426 million. A rise in age is the primary trigger factor for the disease; according to the American College of Cardiology, 25% of older adults above 80 have significant transthyretin amyloid deposits in the myocardium.

Moreover, a rise in the launch of new drugs and favorable government initiatives drives the market in the forecast period. For instance, in January 2022, Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis. The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Also, there is a rise in transthyretin amyloid cardiomyopathy drug launches in the forecast period that help to grow the market the forecast period.

Market Segmentation: The Hospital pharmacies segment is projected to be the dominant segment in the market during the forecast period.

By end-user, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.

Hospital pharmacies are expected to be the largest market shareholder over the forecast period due to the better infrastructure of the hospitals and opting for treatment in hospitals by the majority of the population. Most of the time, medicines are available in hospital pharmacies, and it is easier to get drugs from hospital pharmacies while getting treated in hospitals.

Also, medication is expected to hold the significant market share over the forecast period due to the approval of new drugs by the FDA. For instance, in June 2022, Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced FDA approval for its new product named AMVUTTRA (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults. This new product has the potential to change the standard of care for people living with polyneuropathy of this devastating disease.

Geographical Penetration: North America is the dominating region during the forecast period.

North America is dominating the transthyretin amyloid cardiomyopathy market in 2021. It is estimated to hold the largest market size over the forecast period, owing to a rise in cases of transthyretin amyloid cardiomyopathy, highly aware population, advanced healthcare infrastructure, favorable government initiatives, the introduction of new drugs and presence of major companies in the region. Many companies in the area have a robust pipeline and develop new medicines for transthyretin amyloid cardiomyopathy. Transthyretin amyloid cardiomyopathy is more common in the African-American population of the region, with approximately 4% of African-Americans diagnosed with the disease yearly, as per the National Institute of Health (NIH). Thus, the increase in the patient pool is boosting the market's growth in the region.

Competitive Landscape:

Some of the major key players in the market are Pfizer Inc., Ionis Pharmaceuticals, BridgeBio Pharma, Alnylam Pharmaceuticals, Prothena Corporation, Regeneron Pharmaceuticals, Corino Therapeutics, Arcturus Therapeutics and Proclara Biosciences. Pfizer Inc. holds the leadership position in the transthyretin amyloid cardiomyopathy market due to portfolio expansion, mergers, collaborations, and acquisitions. The key players are adopting various growth strategies such as developing new products, mergers & acquisitions, partnerships, and collaborations and increasing research and development and high investment, contributing to the growth of the transthyretin amyloid cardiomyopathy market. In February 2020, European Commission Approved VYNDAQEL, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM). VYNDAQEL is an oral 61-gram capsule for treating wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy. It is available in two formulations: one for cardiomyopathy and one for stage 1 polyneuropathy. In December 2021, Ionis collaborated with AstraZeneca for the development of commercialized eplontersen. This collaboration is expected to enable faster and deeper market penetration into the growing global TTR amyloidosis market. These companies jointly develop eplontersen in the U.S. AstraZeneca has exclusive rights to commercialize in the rest of the world.

The global transthyretin amyloid cardiomyopathy market report would provide an access to approximately 58 market data tables, 53 figures and 170 pages